Cargando…

IL-6/JAK/STAT3介导苦参碱对K562细胞的增殖抑制作用

OBJECTIVE: To investigate the molecular mechanism of the growth inhibitory effect of matrine on K562 cells in JAK/STAT3 mediated signal pathway. METHODS: Western blot analyses were performed to investigate the differential expression of JAK2, STAT3, phospho-STAT3 (Tyr705 & Ser727) and phospho-JA...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Editorial office of Chinese Journal of Hematology 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7342599/
https://www.ncbi.nlm.nih.gov/pubmed/26031532
http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2015.05.015
_version_ 1783555537729748992
collection PubMed
description OBJECTIVE: To investigate the molecular mechanism of the growth inhibitory effect of matrine on K562 cells in JAK/STAT3 mediated signal pathway. METHODS: Western blot analyses were performed to investigate the differential expression of JAK2, STAT3, phospho-STAT3 (Tyr705 & Ser727) and phospho-JAK2 proteins after matrine treatment in K562 cells with or without human recombinant interleukin 6 (IL-6) pretreatment. The expressions of STAT3 response gene products such as Bcl-xL, Cyclin D1 and c-Myc, were investigated by Western blot and quantitative real time RT-PCR (qRT-PCR). Expression of IL-6, a potent upstream activating factor of JAK/STAT3 pathway, was analyzed by both real time qRT-PCR and ELISA. RESULTS: Western blot revealed that matrine treatment resulted in a strong down-regulation of phospho-STAT3 both in Tyr705 and Ser727 sites or phospho-JAK2 proteins expression without significant effects on the total STAT3 and JAK2 proteins. The expression of phospho-Tyr705 STAT3 and phospho-Ser727 STAT3 was decreased to 0.370±0.024 and 0.700±0.172 in K562 cells treated with 0.5 mg/ml matrine for 48 h, respectively, from 0.690 ± 0.119 and 1.150 ± 0.263 in control cells, accompanied with a dramatical down-regulation of phospho-JAK2 from 0.670±0.137 to 0.049±0.057 (P< 0.05). In addition, it was found that the expression of Bcl-xL, Cyclin D1, c-Myc was decreased both at the transcriptional and protein level in K562 cells after matrine treatment. Matrine treatment resulted in a significant decrease in the expression level of IL-6 in K562 cells from (35.1±1.93) to (10.74±1.83) and (8.66±1.24) pg/ml at the dose of 0.5 and 0.8 mg/ml, respectively (P<0.05). Matrine treatment could diminish the up-regulation of STAT3, JAK2, phospho-STAT3 and phospho-JAK2 protein following pretreatment with IL-6 in K562 cells. CONCLUSION: Matrine exerts its anti-leukemia effect by interfering with the JAK2/STAT3 signaling pathway. The inhibition of IL-6 expression may play a pivotal role in the disruption of JAK/STAT pathway by matrine.
format Online
Article
Text
id pubmed-7342599
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Editorial office of Chinese Journal of Hematology
record_format MEDLINE/PubMed
spelling pubmed-73425992020-07-16 IL-6/JAK/STAT3介导苦参碱对K562细胞的增殖抑制作用 Zhonghua Xue Ye Xue Za Zhi 论著 OBJECTIVE: To investigate the molecular mechanism of the growth inhibitory effect of matrine on K562 cells in JAK/STAT3 mediated signal pathway. METHODS: Western blot analyses were performed to investigate the differential expression of JAK2, STAT3, phospho-STAT3 (Tyr705 & Ser727) and phospho-JAK2 proteins after matrine treatment in K562 cells with or without human recombinant interleukin 6 (IL-6) pretreatment. The expressions of STAT3 response gene products such as Bcl-xL, Cyclin D1 and c-Myc, were investigated by Western blot and quantitative real time RT-PCR (qRT-PCR). Expression of IL-6, a potent upstream activating factor of JAK/STAT3 pathway, was analyzed by both real time qRT-PCR and ELISA. RESULTS: Western blot revealed that matrine treatment resulted in a strong down-regulation of phospho-STAT3 both in Tyr705 and Ser727 sites or phospho-JAK2 proteins expression without significant effects on the total STAT3 and JAK2 proteins. The expression of phospho-Tyr705 STAT3 and phospho-Ser727 STAT3 was decreased to 0.370±0.024 and 0.700±0.172 in K562 cells treated with 0.5 mg/ml matrine for 48 h, respectively, from 0.690 ± 0.119 and 1.150 ± 0.263 in control cells, accompanied with a dramatical down-regulation of phospho-JAK2 from 0.670±0.137 to 0.049±0.057 (P< 0.05). In addition, it was found that the expression of Bcl-xL, Cyclin D1, c-Myc was decreased both at the transcriptional and protein level in K562 cells after matrine treatment. Matrine treatment resulted in a significant decrease in the expression level of IL-6 in K562 cells from (35.1±1.93) to (10.74±1.83) and (8.66±1.24) pg/ml at the dose of 0.5 and 0.8 mg/ml, respectively (P<0.05). Matrine treatment could diminish the up-regulation of STAT3, JAK2, phospho-STAT3 and phospho-JAK2 protein following pretreatment with IL-6 in K562 cells. CONCLUSION: Matrine exerts its anti-leukemia effect by interfering with the JAK2/STAT3 signaling pathway. The inhibition of IL-6 expression may play a pivotal role in the disruption of JAK/STAT pathway by matrine. Editorial office of Chinese Journal of Hematology 2015-05 /pmc/articles/PMC7342599/ /pubmed/26031532 http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2015.05.015 Text en 2015年版权归中华医学会所有 http://creativecommons.org/licenses/by-nc-sa/3.0/ This work is licensed under a Creative Commons Attribution 3.0 License (CC-BY-NC). The Copyright own by Publisher. Without authorization, shall not reprint, except this publication article, shall not use this publication format design. Unless otherwise stated, all articles published in this journal do not represent the views of the Chinese Medical Association or the editorial board of this journal.
spellingShingle 论著
IL-6/JAK/STAT3介导苦参碱对K562细胞的增殖抑制作用
title IL-6/JAK/STAT3介导苦参碱对K562细胞的增殖抑制作用
title_full IL-6/JAK/STAT3介导苦参碱对K562细胞的增殖抑制作用
title_fullStr IL-6/JAK/STAT3介导苦参碱对K562细胞的增殖抑制作用
title_full_unstemmed IL-6/JAK/STAT3介导苦参碱对K562细胞的增殖抑制作用
title_short IL-6/JAK/STAT3介导苦参碱对K562细胞的增殖抑制作用
title_sort il-6/jak/stat3介导苦参碱对k562细胞的增殖抑制作用
topic 论著
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7342599/
https://www.ncbi.nlm.nih.gov/pubmed/26031532
http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2015.05.015
work_keys_str_mv AT il6jakstat3jièdǎokǔcānjiǎnduìk562xìbāodezēngzhíyìzhìzuòyòng
AT il6jakstat3jièdǎokǔcānjiǎnduìk562xìbāodezēngzhíyìzhìzuòyòng
AT il6jakstat3jièdǎokǔcānjiǎnduìk562xìbāodezēngzhíyìzhìzuòyòng
AT il6jakstat3jièdǎokǔcānjiǎnduìk562xìbāodezēngzhíyìzhìzuòyòng
AT il6jakstat3jièdǎokǔcānjiǎnduìk562xìbāodezēngzhíyìzhìzuòyòng
AT il6jakstat3jièdǎokǔcānjiǎnduìk562xìbāodezēngzhíyìzhìzuòyòng
AT il6jakstat3jièdǎokǔcānjiǎnduìk562xìbāodezēngzhíyìzhìzuòyòng
AT il6jakstat3jièdǎokǔcānjiǎnduìk562xìbāodezēngzhíyìzhìzuòyòng
AT il6jakstat3jièdǎokǔcānjiǎnduìk562xìbāodezēngzhíyìzhìzuòyòng